3O8 Stock Overview
A clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Omeros Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.64 |
| 52 Week High | US$12.39 |
| 52 Week Low | US$2.99 |
| Beta | 2.42 |
| 1 Month Change | -39.32% |
| 3 Month Change | -57.92% |
| 1 Year Change | 21.22% |
| 3 Year Change | 37.82% |
| 5 Year Change | -72.49% |
| Change since IPO | -20.95% |
Recent News & Updates
Recent updates
Shareholder Returns
| 3O8 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -35.3% | -4.1% | 1.2% |
| 1Y | 21.2% | -27.8% | 14.0% |
Return vs Industry: 3O8 exceeded the German Pharmaceuticals industry which returned -24.3% over the past year.
Return vs Market: 3O8 exceeded the German Market which returned 12.6% over the past year.
Price Volatility
| 3O8 volatility | |
|---|---|
| 3O8 Average Weekly Movement | 15.5% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in DE Market | 13.0% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 3O8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3O8's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 202 | Greg Demopulos | www.omeros.com |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company’s lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; zaltenibart that is in phase 3 clinical trials for Paroxysmal nocturnal hemoglobinuria; in phase 2 clinical trial for the treatment complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
Omeros Corporation Fundamentals Summary
| 3O8 fundamental statistics | |
|---|---|
| Market cap | €204.07m |
| Earnings (TTM) | -€163.33m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs 3O8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 3O8 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$71.55m |
| Gross Profit | -US$71.55m |
| Other Expenses | US$111.08m |
| Earnings | -US$182.63m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.15 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -221.2% |
How did 3O8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/15 06:35 |
| End of Day Share Price | 2025/05/15 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Omeros Corporation is covered by 20 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Jason Kolbert | B. Riley Wealth |
| Ritu Baral | Canaccord Genuity |